We Are Attending BIO International 2024

At BIOVECTRA we specialize in clinical-to-commercial scale production capabilities for:

  • Cannabinoid therapeutics  
  • Synthetic small molecules 
  • Fermented small molecules
  • pDNA/mRNA
  • Highly potent APIs
  • Biologics 
  • Bioreagents

We Are Attending BIO International 2024

At BIOVECTRA we specialize in clinical-to-commercial scale production capabilities for:

  • Cannabinoid therapeutics  
  • Synthetic small molecules 
  • Fermented small molecules
  • pDNA/mRNA
  • Highly potent APIs
  • Biologics 
  • Bioreagents

Meet With Us!

Complete the form below to schedule time to meet with the BIOVECTRA team during this event!

We are here to help you make the right decisions to achieve your financial goals

Lorem ipsum dolor sit amet, consectet adipiscing elised do eiusm porla tolos incididunt ut labore et dolore magna aliqu minlom veniam the quis nostrud exercitation.

Financial Checkup

Lorem ipsum dolor sit amet, consectet adipiscing elied do usm pora tolos incididunt ut labore.

Financial Planning

Lorem ipsum dolor sit amet, consectet adipiscing elied do usm pora tolos incididunt ut labore.

Investment Consulting

Lorem ipsum dolor sit amet, consectet adipiscing elied do usm pora tolos incididunt ut labore.

Inheritance Tax Planning

Lorem ipsum dolor sit amet, consectet adipiscing elied do usm pora tolos incididunt ut labore.

Norman & Turner,
Experienced Financial Planning & Investment Advisors

Our mission is to guide clients through these uncertain times with professional financial advice. To help them make the right decisions to secure their financial future.

Ruben Norman

Founder, CFP
Lorem ipsum dolor sikot amet the conec acing elit sed eiusm pora off incdunt oldar labore dolore malgna veniam nostrud exeion ullam.

Marvin Turner

Co-Founder, CFP
Lorem ipsum dolor sikot amet the conec acing elit sed eiusm pora off incdunt oldar labore dolore malgna veniam nostrud exeion ullam.

Brett Loremous

Construction Manager at Ammigle

“I can’t say enough about the excellent consultation and advice I have received from Norman & Turner through the years. They took the time to really understand my financial goals and never treated me like “just another Client”. Their assistance with personal and corporate income tax, investments, and retirement has been invaluable. I’v been able to achieve more then expected thanks to them.”

Emily Reloupod

Retired business owner

“Norman & Turner has been excellent in their handling of our financial affairs. They were able to explain complex financial matters to us in an easy and understandable way. They explained all the options available to us, which helped us make better decisions. They are extremely knowledgable, friendly, and caring and we were very impressed by them. Highly recommended!”

Client Testimonials

Lorem ipsum dolor sikot amet the consec acing elit sed dllo eiusm pora inciunt old labore dolore magna aliqua enim veniam quis nostrud extion.

Contact us today

Get A free initial financial consultation

Book Free Consultation
  • +1-416-555-0188
  • 315 St Germain Ave, Toronto ON M5M 1W4
Facebook-f Twitter Linkedin-in
Norman & Turner Financial Advisers

SEO plus – Test

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Normand Blais – Senior Director Development & Innovation, Biologics

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors